Geron's blood disorder drug gets FDA advisers' backing

Geron

14/03/2024 19:23

March 14 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Thursday voted in favor of Geron's  GERN.O 
blood disorder drug,
stating that, based on late-stage trial data, the benefits
outweigh treatment associated risks in patients.
    
    


 (Reporting by Pratik Jain and Christy Santhosh in Bengaluru;
Editing by Krishna Chandra Eluri)
 ((Pratik.Jain@thomsonreuters.com;))